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Abstract: Increased longevity and population aging will increase the number of men with late 
onset hypogonadism. It is a common condition, but often underdiagnosed and undertreated. The 
indication of testosterone-replacement therapy (TRT) treatment requires the presence of low 
testosterone level, and symptoms and signs of hypogonadism. Although controversy remains 
regarding indications for testosterone supplementation in aging men due to lack of large-scale, 
long-term studies assessing the benefits and risks of testosterone-replacement therapy in men, 
reports indicate that TRT may produce a wide range of benefits for men with hypogonadism 
that include improvement in libido and sexual function, bone density, muscle mass, body 
composition, mood, erythropoiesis, cognition, quality of life and cardiovascular disease. Per-
haps the most controversial area is the issue of risk, especially possible stimulation of prostate 
cancer by testosterone, even though no evidence to support this risk exists. Other possible risks 
include worsening symptoms of benign prostatic hypertrophy, liver toxicity, hyperviscosity, 
erythrocytosis, worsening untreated sleep apnea or severe heart failure. Despite this contro-
versy, testosterone supplementation in the United States has increased substantially over the 
past several years. The physician should discuss with the patient the potential benefits and risks 
of TRT. The purpose of this review is to discuss what is known and not known regarding the 
benefits and risks of TRT.
Keywords: hypogonadism, testosterone replacement therapy, erectile dysfunction, osteoporosis, 
cardiovascular disease
Introduction
Hypogonadism is a clinical condition in which low levels of serum testosterone are 
found in association with specific signs and symptoms. When hypogonadism occurs 
in an older man, the condition is often called andropause or androgen deficiency 
of the aging male or late onset hypogonadism (LOH).1 The most easily recognized 
clinical signs of relative androgen deficiency in older men are a decrease in muscle 
mass and strength, a decrease in bone mass and osteoporosis, and an increase in 
central body fat. However, symptoms such as a decrease in libido and sexual desire, 
forgetfulness, loss of memory, anemia, difficulty in concentration, insomnia, and a 
decreased sense of well-being are more difficult to measure and differentiate from 
hormone-independent aging. This condition may result in significant detriment to 
quality of life and adversely affect the function of multiple organ systems.1–3 A health 
factor-independent, age-related longitudinal decrease in serum testosterone levels 
has been reported.4 This LOH is important since it features many potentially serious 
consequences that can be readily avoided or treated, and the affected sector of the Therapeutics and Clinical Risk Management 2009:5 428
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population is currently expanding in number. Prospective 
population-based studies reported in the past decade indicate 
that low testosterone levels are associated with an increase 
in the risk for developing type 2 diabetes mellitus and 
metabolic syndrome and possibly a reduction in survival. 
Results were similar for bioavailable testosterone.5–7 In men, 
endogenous testosterone concentrations are inversely related 
to mortality due to cardiovascular disease and all causes. Low 
testosterone may be a predictive marker for those at high risk 
of cardiovascular disease.8 Also, low testosterone levels were 
associated with increased mortality in male veterans9 but this 
association could not be confirmed in the Massachusetts Male 
Aging Study10 or the New Mexico Aging Study.11
As the clinical symptoms of hormone deficiency in older 
males may be nonspecific, and since a substantial number of 
relatively asymptomatic elderly men have testosterone levels 
outside the normal range for young adults, investigators 
have suggested that testosterone replacement therapy is only 
warranted in the presence of both clinical symptoms sugges-
tive of hormone deficiency and decreased hormone levels.12 
Restoring serum testosterone levels to the normal range using 
testosterone replacement therapy results in clinical benefits in 
some of these areas. Successful management of testosterone 
replacement therapy requires appropriate evaluation and an 
understanding of the benefits and risks of treatment.
Aging and hypogonadism
Due to the baby boom that occurred after World War II, 
the percentage of population in the older age group in 
developed countries is increasing. Testosterone deficiency 
is a common disorder in middle-aged and older men but 
it is underdiagnosed and often untreated. Clinicians tend 
to overlook it, and the complaints of androgen-deficient 
men are merely considered part of aging. Hypogonadism 
affects an estimated 2 million to 4 million men in the United 
States. Many patients can derive significant benefits from 
treatment. Testosterone supplementation in the United States 
has increased substantially over the past several years.13 
However, it has been estimated that only 5% of affected men 
currently receive treatment.
The decline of serum testosterone levels appears to be 
a gradual, age-related process resulting in an approximate 
1% annual decline after age 30. In cross-sectional and 
longitudinal studies of men aged 30 or 40 years and above, 
total, bioavailable and free testosterone concentrations fall 
with increasing age with a steeper decline in bioavailable and 
free compared with total testosterone concentrations.4,14,15 In 
older men above the age of 65 or 70 years, the changes in total 
testosterone are overshadowed by a more significant decline 
in free testosterone levels.16,17 This is a consequence of the 
age-associated increase of the levels of sex hormone binding 
globulin (SHBG) demonstrated by cross-sectional studies, 
and has now been confirmed by longitudinal studies.18,19 
Although the fall is gradual, by the eighth decade, according 
to the Baltimore Longitudinal Study, 30% of men had total 
testosterone values in the hypogonadal range, and 50% had 
low free testosterone values. The rate of age-related decline 
in serum testosterone levels varies in different individuals 
and is affected by chronic disease and medications.20 There 
is evidence that many of these men are not symptomatic.21
Multiple mechanisms are likely to influence the decline 
in testosterone levels in aging men.22 Lower testosterone 
levels may result from reduced testicular responses to 
gonadotrophin stimuli with aging, coupled with incomplete 
hypothalamo–pituitary compensation for the fall in total 
and free testosterone levels.23,24 Whether the age-dependent 
decline in androgen levels leads to health problems in older 
men is being debated vigorously.21,25
Diagnosis
At present, the diagnosis of hypogonadism requires 
the presence of symptoms and signs suggestive of 
testosterone deficiency.1,26 The symptom most associated 
with hypogonadism is low libido.27–29 Other manifestations 
of hypogonadism include erectile dysfunction, decreased 
muscle mass and strength, increased body fat, decreased 
bone mineral density and osteoporosis, mild anemia, 
breast discomfort and gynecomastia, hot flushes, sleep 
disturbance, body hair and skin alterations, decreased vitality, 
and decreased intellectual capacity (poor concentration, 
depression, fatigue).30 The problem is many of the symptoms 
of late life hypogonadism are similar in other conditions31,32 or 
are physiologically associated with the aging process.33 One 
or more of these symptoms must be corroborated with a low 
serum testosterone level.21,25,34 Depression, hypothyroidism 
and chronic alcoholism should be excluded, as should the 
use of medications such as corticosteroids, cimetidine, 
spironolactone, digoxin, opioid analgesics, antidepressants 
and antifungal drugs. Of course, diagnosis of LOH should 
never be undertaken during an acute illness, which is likely 
to result in temporarily low testosterone levels (Figure 1).
The problem with symptoms associated with low serum 
testosterone is that they may be found in other conditions, 
which become increasingly common as men age. While 
the questionnaires, the Androgen Deficiency in Aging 
Male (ADAM)35,36 and the Aging Male Symptoms Scale Therapeutics and Clinical Risk Management 2009:5 429
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SYMPTOMS
ADAM   
Is patient depressed?  Yes
Treat
depression 
No
Less than
300 ng/dL  
Testosterone
level 
Symptoms
remain
300–500
ng/dL 
Bioavailable
testosterone 
TREATMENT
TRIAL  
Low
Figure 1 Approach to the diagnosis and treatment of late onset hypogonadism 
(ADAM = St. Louis University Androgen Deficiency in Aging Males Questionnaire).
(AMS)37,38 (Table 1), may be sensitive markers of the low 
testosterone state (97% and 83%, respectively), they are not 
tightly correlated with low testosterone (specificity 30% and 
39%), particularly in the borderline low serum testosterone 
range. Therefore, questionnaires are not recommended for 
screening of androgen deficiency in men receiving health care 
for unrelated reasons.26 Moreover, healthy ambulatory elderly 
males over 70, assessed by the AMS, had a high perception 
of sexual symptoms with mild psychological and mild to 
moderate somatovegetative symptoms.39 Note also that there 
is marked inter-individual variation of the testosterone level 
at which symptoms occur.28,34,40 A low libido by itself is 
insufficient to allow the diagnosis of hypogonadism.41
Laboratory diagnosis
A thorough physical and biochemical work-up is necessary. 
Transient decreases of serum testosterone levels such as 
those due to acute illnesses should be excluded by careful 
clinical evaluations and repeated hormone measurement. 
Hypogonadism (primary or secondary) can occur at all ages, 
including in elderly men. Risk factors for hypogonadism 
in older men may include chronic illnesses (including 
diabetes mellitus, chronic obstructive lung disease, and 
inflammatory arthritic, renal, and HIV-related diseases), 
obesity, metabolic syndrome, and hemachromatosis.26 
Such chronic diseases should be investigated and treated.42 
Primary hypogonadism is characterized by raised levels of 
luteinizing hormone (LH) and follicle-stimulating hormone 
(FSH) in response to diminished testosterone (and estradiol 
and inhibin B) feedback. Secondary hypogonadism is 
characterized by low levels of testosterone associated with 
low or normal levels of FSH and/or LH.43 However, in older 
men, the figure is less clear-cut, testosterone deficiency being 
both primary and secondary.
Serum testosterone has a diurnal variation and levels peak 
between 08.00 and 10.00 h, a serum sample should be obtained 
between 07.00 and 11.00 h.44 The most widely accepted 
parameters to establish the presence of hypogonadism is the 
measurement of serum total testosterone. Total testosterone 
levels above 500 ng/dL do not require substitution; patients 
with serum total testosterone levels below 300 ng/dL will 
usually benefit from testosterone treatment. If the serum 
total testosterone level is between 230 and 350 ng/dL in 
males under 50 years or between 300 and 500 ng/dL in older 
males, repeating the measurement of total testosterone with 
sex hormone binding globulin (SHBG) to calculate free 
testosterone or measuring free testosterone by equilibrium 
dialysis or bioavailable testosterone is recommended.45 Note 
that SHBG is elevated in elderly patients and effected by many 
diseases.30 Measurements of serum LH will assist in differ-
entiating between primary and secondary hypogonadism and 
serum prolactin is indicated when the serum testosterone is 
lower than 150 ng/dl46–49 or when secondary hypogonadism is 
suspected.50,51 Measurement of free or bioavailable testosterone 
(BT, free plus albumin bound) should be considered when 
the serum total testosterone concentration is not diagnostic of 
hypogonadism, particularly in obese men. Bioavailable testos-
terone appears to correlate better with potential hypogonadal 
symptoms than does total testosterone.52 A free testosterone 
level below 65 pg/mL can provide supportive evidence for 
testosterone treatment.53,54 The gold standard for bioavailable 
testosterone measurement is by sulphate precipitation and 
equilibrium dialysis for free testosterone. However, both 
techniques are not usually available in local laboratories so 
that calculated values seem preferable. Salivary testosterone, Therapeutics and Clinical Risk Management 2009:5 430
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a proxy for unbound testosterone, has also been shown to be 
a reliable substitute for free testosterone measurements.55–57 
Diagnosis of late life hypogonadism requires both symptoms 
and low testosterone (Figure 1).
Treatment and delivery systems
Testosterone replacement therapy aims at restoring hormone 
levels in the normal range of young adults and should, in 
theory, approximate the natural, endogenous production 
of the hormone produces and maintains physiologic serum 
concentrations of the hormone and its active metabolites 
without significant side effects or safety concerns and, more 
importantly, alleviates the symptoms suggestive of the 
hormone deficiency. However, the ultimate goals are to main-
tain or regain the highest quality of life, to reduce disability, 
to compress major illnesses into a narrow age range, and to 
add life to years.
Several different types of testosterone replacement exist 
including tablets, injections, transdermal systems, oral, 
pellets, and buccal preparations of testosterone. Selective 
androgen receptor modulators (SARMs) are under develop-
ment but not yet clinically available.
The selection of the preparation should be a joint decision of 
an informed patient and physician.58 Short-acting preparations 
may be preferred over long-acting depot preparations in the 
initial treatment of patients with LOH.59 It has been recom-
mended that the optimal serum testosterone level for efficacy 
and safety should be in the mid range to lower young-adult-male 
serum testosterone levels as the therapeutic goal.60 However, 
older males need higher levels to obtain a therapeutic benefit.
Oral agents
The oral form of 17-alpha-alkylated androgen should not 
be used because of their potential liver toxicity including 
the development of benign and malignant neoplasm61 in 
addition deleterious effects on levels of both LDL cholesterol 
(LDL-C) and HDL cholesterol (HDL-C).62 Testosterone 
undecanoate, which is absorbed predominantly through the 
lymphatic system, is widely used outside the United States 
and has the best safety data. However, it can rarely raise 
testosterone levels above the mid-range.
intramuscular injection
Until recently, testosterone cypionate and enanthate were 
frequently used by intramuscular injection of short-acting 
testosterone esters that usually produces supraphysiological 
peaks and hypogonadal troughs in testosterone levels. These 
fluctuations in testosterone levels may yield variations in 
libido, sexual function, energy, and mood.63 A “roller coaster” 
effect can also occur, characterized by alternating periods 
of symptomatic benefit and a return to base-line symptoms, 
corresponding to the fluctuations in serum testosterone 
levels.64,65 However, in our experience many males eventually 
prefer this form of therapy to the others. Compared with 
conventional testosterone enanthate or cypionate treatment 
requiring injection intervals of 2 to 3 weeks, and resulting in 
supraphysiological serum testosterone levels, injections of 
testosterone undecanoate (TU) at intervals of up to 3 months 
offer an excellent alternative for substitution therapy of 
male hypogonadism.66 The long duration of action creates a 
problem if there are complications of testosterone therapy.
Transdermal systems
Currently, transdermal testosterone is available in either a 
scrotal or a nonscrotal skin patch and more recently as a gel 
preparation, allowing a single application of this formulation 
to provide continuous transdermal delivery of testosterone 
for 24 hours, producing circulating testosterone levels that 
approximate the normal levels (eg, 300 to 1000 ng/dL) 
seen in healthy men. Daily application is required for 
each of these. They are designed to deliver 5 to 10 mg of 
testosterone per day. Scrotal patches produce high levels 
of circulating dihydrotestosterone (DHT) due to the high 
5-alpha-reductase enzyme activity of scrotal skin. The 
advantages include ease of use and maintenance of relatively 
uniform serum testosterone levels over time,67 in addition to 
their efficacy in providing adequate testosterone replacement 
therapy.68 A reservoir-type transdermal delivery system of 
testosterone (TS) was developed using an ethanol/water 
(70:30) cosolvent system as the vehicle. This device is 
available in Europe as a body patch without reservoir and 
applied every 2 days.69
Table 1 Androgen Deficiency In Ageing Male (ADAM) questionnaire
  1.  Do you have a decrease in libido or sex drive?
  2.  Do you have a lack of energy?
  3.  Do you have a decrease in strength and/or endurance?
  4.  Have you lost weight?
  5.  Have you noticed a decreased “enjoyment of life”?
  6. Are you sad and/or grumpy?
  7. Are your erections less strong?
  8.    Have you noticed a recent deterioration in your ability to play sports?
  9. Are you falling asleep after dinner?
10.  Has there been a recent deterioration in your work performance?
A positive ADAM questionnaire was defined as “yes” for question 1 and 7, and 2–4 
for all other items.Therapeutics and Clinical Risk Management 2009:5 431
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Skin irritation may be associated with the use of 
transdermal systems especially with testosterone patches 
but is uncommon with gel preparations.70 At present the two 
testosterone gel preparations (Androgel® and Testim®) are 
the most commonly used in the United States.
Sublingual and buccal
Cyclodextrin-complexed testosterone sublingual formulation 
is absorbed rapidly into circulation, where testosterone is 
released from the cyclodextrin shell.71 This formulation has 
been suggested to have a good therapeutic potential, after 
adjustment of its kinetics, to produce physiologic levels of 
testosterone.
A novel sustained-release mucoadhesive buccal 
testosterone tablet (Striant®; Columbia Laboratories, Inc.), 
delivering 30 mg, applied to the upper gum region above 
the lateral incisors twice daily, in the morning and evening, 
approximately 12 hours apart. This formulation has been 
shown to restore serum testosterone concentrations to the 
physiological range within 4 hours of application, with 
steady-state concentrations achieved within 24 hours of 
twice-daily dosing72 and achieves testosterone levels within 
the normal range.73 Studies indicate that Striant® is an 
effective, well-tolerated, convenient and discreet treatment 
for male hypogonadism.74 However, it has had minimal 
clinical uptake, due to the difficulty of maintaining the buccal 
treatment in the mouth.
Subdermal implants
Subdermal testosterone implants still offer the longest 
duration of action with prolonged zero-order, steady-state 
delivery characteristics lasting 4 to 7 months.75,76 The 
standard dosage is four 200 mg pellets (800 mg) implanted 
subdermally at intervals of 5 to 7 months.77 Yet the in vivo 
testosterone release rate of these testosterone pellets and its 
determinants have not been studied systematically. However 
the risk of infection at the implant site and extrusion of the 
pellets which occurs in 5% to 10% of cases even with the 
most experienced limit their use.
Benefits of testosterone 
replacement therapy
Restoring testosterone levels to within the normal range by 
using testosterone replacement therapy can improve many of 
the effects of hypogonadism. Most importantly, these include 
beneficial effects on mood, energy levels and patients’ sense 
of well-being, sexual function, lean body mass and muscle 
strength, erythropoiesis and bone mineral density (BMD), 
cognition and some benefits on cardiovascular risk factors. 
These are summarized in Table 2. Testosterone is well 
known to help in libido, bone density, muscle mass, body 
composition, mood, erythropoiesis, and cognition. All these 
benefits made testosterone replacement therapy in the United 
States increase substantially over the past several years, 
with an increase of more than 500% in prescription sales of 
testosterone products since 1993.
Improved sexual desire, function  
and performance
The prevalence of erectile dysfunction increases markedly 
with age.78,79 Serum-free testosterone was significantly 
correlated with erectile and orgasmic function domains of the 
International Index of Erectile Function (IIEF) questionnaire. 
Men with greater sexual activity had higher bio-T levels 
than men with a lower frequency and androgen deficiency 
may contribute to the age-related decline in male sexuality; 
correspondingly low levels of bio T were associated with low 
sexual activity.80,81 Compared with younger men, elderly men 
require higher levels of circulating testosterone for libido and 
erectile function.82,83 However, erectile dysfunction and/or 
diminished libido with or without a testosterone deficiency, 
might be related to other comorbidities or medications.84
Men with erectile dysfunction (ED) and/or diminished 
libido and documented testosterone deficiency are candidates 
for testosterone therapy. Adequate testosterone treatment 
can restore venous leakage in the corpus cavernosum 
which is a frequent etiological factor in ED in elderly 
men.85 Overviews of randomized controlled clinical trials 
indicate some benefit of testosterone therapy on sexual 
health-related outcomes; however further investigation in 
this area is warranted particularly in older men who are not 
clearly hypogonadal.86,87 Long-term follow-up of testosterone 
replacement in hypogonadal males and a control group 
indicates that self-assessment of libido was significantly 
higher in the testosterone-treated group.88 Testosterone 
replacement has also been shown to enhance libido and 
the frequency of sexual acts and sleep-related erections.89,90 
Wang et al67 also reported improvement of sexual function; 
Table 2 Potential benefits of testosterone replacement therapy
Improve sexual desire and function
increase bone mineral density
Improve mood, energy and quality of life
Change body composition and improve muscle mass and strength
Improve cognitive functionTherapeutics and Clinical Risk Management 2009:5 432
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however, their data suggest that there is a threshold level 
of T above which there is no further enhancement of 
response. On the other hand, Two placebo-controlled trials 
reported on the effect of testosterone on overall sexual 
satisfaction, yielding imprecise results.91,92 Transdermal 
testosterone replacement therapy, in particular, has been 
linked to positive effects on fatigue, mood, and sexual 
function, as well as significant increases in sexual activity.93 
1% hydroalcoholic testosterone gel is an effective and safe 
treatment option in subjects with ED.94
In the presence of a clinical picture of testosterone 
deficiency and borderline serum testosterone levels, a short 
therapeutic trial may be tried.95 An inadequate response to 
testosterone treatment requires reassessment of the causes 
of the erectile dysfunction.45 There is evidence that the 
combined use of testosterone and phosphodiesterase type 
5 inhibitors in hypogonadal or borderline eugonadal men 
have a synergetic effect.96–101 The combination treatment 
should be considered in hypogonadal patients with erectile 
dysfunction (ED) failing to respond to either treatment 
alone. Testosterone produces this effect by enhancing the 
production of nitric oxide synthase. It is unclear whether 
PDE5-I, testosterone, or the combination of the two should 
be started first in men with hypogonadism and ED.45 All 
men with ED should be screened for hypogonadism before 
treating for erectile dysfunction.102
In addition to improvement in sexual function, testosterone 
therapy may also improve lower urinary tract symptomatology 
(LUTS)/bladder functions by increasing bladder capacity 
and compliance and decreasing detrusor pressure at maximal 
flow in men with SLOH.103 However, the role of testosterone 
supplementation in men with erectile dysfunction who are not 
androgen deficient or in the low to normal range needs further 
investigation to determine whether testosterone therapy will 
improve erectile function in older men and to weigh the 
risk–benefit ratio for testosterone therapy in this setting.86
Bone mineral density
Chronically ill men may have both apparent androgen 
deficiency and low bone mass.104 Osteopenia, osteoporosis, 
and fracture prevalence rates are greater in hypogonadal 
younger and older men.105 The prevalence of osteoporosis 
in testosterone deficient males is double that of those with 
normal testosterone level.106,107 Testosterone plays a major 
role in BMD.108 Bone density in hypogonadal men of all ages 
increases under testosterone substitution provided the dose 
is high enough;109–111 although normal adult bone mass is not 
reached.112 Testosterone produces this effect by increasing 
osteoblastic activity and through aromatization to estrogen 
reducing osteoclastic activity. The role of the partial androgen 
deficiency in aging males in bone fracture rate remains to 
be established.113 Patients with prostate cancer treated with 
androgen deprivation therapy have an increased risk of 
osteoporotic fracture.114 The long-term benefit of testosterone 
requires further investigation. However, the correlation with 
bioestradiol, the levels of which decline in elderly males, was 
even stronger, suggesting that part of the androgen effects 
on bone are at least partially indirect, mediated via their 
aromatization.115,116 An increase in osteocalcin levels, an 
index of osteoblast activity was observed,90 and a decrease 
of hydroxyproline excretion, an index of bone resorption 
also was noted.117
Assessment of bone density at 2-year intervals is advisable 
in hypogonadal men, and serum testosterone measurements 
should be obtained in all men with osteopenia.118,119 Trials 
of the effects of testosterone replacement therapy on bone 
mineral density yielded mixed results.120 Increases in spinal 
bone density have been realized in hypogonadal men,121 with 
most treated men maintaining bone density above the fracture 
threshold.122 An improvement in both trabecular and cortical 
bone mineral density of the spine was seen, independent of 
age and type of hypogonadism; in addition, a significant 
increase in paraspinal muscle area has been observed, 
emphasizing the clinical benefit of adequate replacement 
therapy for the physical fitness of hypogonadal men.123 The 
pooled results of a meta-analysis suggest a beneficial effect 
on lumbar spine bone density and equivocal findings on 
femoral neck BMD. Trials of intra muscular testosterone 
reported significantly larger effects on lumbar bone 
density than trials of transdermal testosterone, particularly 
among patients receiving chronic glucocorticoids.124 Also 
in eugonadal men with osteoporosis, Testosterone esters 
(250 mg/2 weeks) increased BMD;125 again, the effects in 
elderly men are less convincing, though the 3 year study of 
Amory et al126 showed a significant increase in hip BMD. 
None of studies have been large enough to show a fracture 
risk reduction with testosterone replacement therapy.
improved body composition and muscle 
mass and strength
The aging process is accompanied by significant changes in 
body composition characterized by decreased fat free mass 
and increased and redistributed fat mass. These changes can 
impose functional limitations and increase morbidity.127,128 
Maximal muscle strength correlates with muscle mass 
independently of age.129 In men, declining testosterone levels Therapeutics and Clinical Risk Management 2009:5 433
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that occur with aging can be a contributing factor to these 
changes by direct effect on muscle cells by testosterone 
or by stimulating IGF-1 expression directly and indirectly 
leading to increased muscle protein synthesis and growth.130 
Epidemiologic studies have demonstrated a correlation 
between bioavailable testosterone concentrations and fat-free 
mass;131 however the correlation with grip strength is not 
clear.131,132
Testosterone replacement may be effective in reversing 
age-dependent body composition changes and associated 
morbidity.133 Testosterone administration improves body 
composition decrease of fat mass, increase of lean body 
mass.134–136 In most of these studies, the body weight change 
did not differ significantly. After androgen supplementation 
to elderly men, generally at a biweekly dose of 200 mg 
T enanthate, there is a relatively modest increase in muscle 
mass (±2 kg)117 and/or arm circumference and grip strength, 
whereas fat mass was decreased modestly.137–139
Testosterone therapy was associated with a greater 
improvement in grip strength than placebo.135,139,140 Changes 
in lower-extremity muscle strength and measures of physical 
function were reported in only a few studies and were 
inconsistent. Recent cross-sectional studies showed that 
in aging men there are also positive correlations between 
testosterone and muscle strength parameters of upper and 
lower extremities, as measured by leg extensor strength and 
isometric hand grip strength.141 Moreover, testosterone was 
positively associated with functional parameters, including 
the doors test as well as “get up and go” test, and 5-chair sit/
stand test.142 On the other hand, some reported an increase in 
lean body mass (LBM) but no change in physical function,92 
or an increase in strength of knee extension or flexion.
Although there is a potential role of testosterone in the 
management of frailty, we do not know whether testosterone 
replacement improves physical function and other health-
related outcomes, or reduces the risk of disability, falls, 
or fractures in older men with low testosterone levels in 
addition to the long-term risks and benefits of testosterone 
supplementation in older men.143
Mood and energy and quality of life
Men older than 50 years with low free testosterone levels had 
poorer quality of life. Hypogonadal men commonly complain 
of loss of libido, dysphoria, fatigue, and irritability.67,70,144,145 
These symptoms overlap with signs and symptoms of major 
depression. There is significant inverse correlation between 
bioavailable testosterone and a depression score in elderly 
men, independent of age and weight but not with total 
testosterone levels.146 There was a reduced libido and reduced 
feelings of well being and minimal effect on mood in patients 
with induced testosterone deficiency; the depressive symptoms 
during the hypogonadal state were reversed by testosterone 
replacement.147 One study showed that the relationship 
between testosterone level and depression was nonlinear and 
may be idiosyncratic.148 The risk of depression was increased 
for hypogonadal and hypergonadal men, but this effect was 
only detectable in underweight and obese men, not in ‘normal’ 
weight men in whom a linear decrease in the risk of depression 
with increasing testosterone level was noted.149
Testosterone replacement therapy has variable effects 
on mood, energy and sense of well being. The results of 
placebo-controlled randomized trials on testosterone’s effect 
on quality of life and depressive mood were inconsistent 
across trials and imprecise.150–152 Testosterone administered 
to nondepressed eugonadal men at physiological doses, did 
not result in significant effects on mood.153,154 Administration 
of supraphysiological doses of testosterone to eugonadal 
men has been associated with mania in a small proportion 
of men.155,156
In hypogonadal men, testosterone replacement was 
associated with improved mood and well-being, and reduced 
fatigue and irritability.157–159 Randomized controlled trials 
of testosterone therapy in men without or with underlying 
chronic illness using a variety of testosterone formulations 
report equivocal improvements in quality of life measures, 
including general well-being and fatigue.41,86,160 Testosterone 
replacement of hypogonadal men with MDD might be an 
effective antidepressant161,162 or augmentation to partially 
effective antidepressant,163 Testosterone gel had significantly 
greater improvement as augmentation therapy in depressive 
symptoms than subjects receiving placebo in hypogonadal 
men with selective serotonin reuptake inhibitor (SSRI) 
partial response.164 In one study, the improvements in 
mood persisted.67 These significant correlations with 
T levels were only observed when T levels were below 
the normal range, which suggests that once a minimally 
adequate T/dihydrotestosterone (DHT) level was achieved, 
further increase did not further contribute to improvement 
of mood.67,157 However, the studies reported tend to be of 
limited size and duration, with a lack of large-scale trials 
with extended long-term follow-up. In HIV-infected men, 
testosterone therapy was well tolerated and effective in 
ameliorating symptoms of hypogonadism. For patients with 
major depression and/or dysthymia, improvement was equal 
to that achieved with standard antidepressants with significant 
improvement in depression inventory score. This effect may Therapeutics and Clinical Risk Management 2009:5 434
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be a direct effect of testosterone or related to positive effects 
of testosterone on weight and/or other anthropometric 
indices. Additional studies are needed to assess the effects 
of testosterone on clinical depression indices in human 
immunodeficiency virus-infected patients.165,166
On the other hand, several placebo-controlled testosterone 
replacement studies did not show a testosterone-placebo 
difference distinguishable with respect to mood.150,164,167,168 
No relationship between testosterone level and depressive 
symptoms was found in the Massachusetts Male Aging Study 
(MMAS).14 This discrepancy in the results of the effects of 
testosterone replacement therapy on mood may be explained 
by the genetic polymorphism in the androgen receptor 
which defines a vulnerable group in whom depression is 
expressed when testosterone levels fall below a particular 
threshold.169,170
Finally, the available controlled studies using exogenous 
testosterone for depression in elderly men are limited, and 
testosterone treatment must be considered experimental. 
The best candidates for treatment may be hypogonadal men 
who are currently taking an existing antidepressant with 
inadequate response.171–173 Additional studies have been 
recommended incorporating vitality, well-being and/or 
quality of life as end points.
Cognitive function
Subclinical androgen deficiency was hypothesized to enhance 
the expression of AD related peptides in vivo.174 Age-related 
decreases in bioavailable T predicted age-related decline 
in visual and verbal memory.175 Men with a higher ratio of 
total testosterone to SHBG predict a reduced incidence of 
Alzheimer’s disease176 and patients with Alzheimer’s disease 
had a lower ratio of total testosterone to SHBG compared 
with age-matched controls.177 In the Baltimore Longitudinal 
Study of Aging (BLSA), a prospective longitudinal 
study176 risk for AD was reduced by 26% for each 10 unit 
(nmoL/nmoL) increase in free T at 2, 5 and 10 years prior 
to AD diagnosis. Altered T levels in AD may precede rather 
than follow diagnosis.
There is good evidence for a strong correlation between 
T levels and cognitive performance such as spatial abilities 
or mathematical reasoning.178 Higher bioavailable and free 
testosterone concentrations have each been associated 
with better performance in specific aspects of memory 
and cognitive function, with optimal processing capacity 
found in men ranging from 35 to 90 years of age even 
after adjustment for potential confounders including age, 
educational attainment and cardiovascular morbidity;179–181 
whereas total testosterone was not.182 However, contradictory 
findings have also been reported, two cross-sectional studies 
did not show a relationship between total or free testosterone 
and measures of working memory, speed/attention or 
spatial relations in men aged from 48 to 80 years.184 In 
another cross-sectional analyses of similarly aged men, no 
association was found between lower free testosterone levels 
and higher performance on spatial visualization tasks, and 
between higher free and total testosterone levels and poorer 
verbal memory and executive performance; however there 
is correlation with faster processing speed.184,185 A possible 
source of conflicting results in these studies may stem from 
interactions between testosterone levels and other risk 
factors for cognitive impairment such as apolipoprotein E 
4 genotype186 and systemic illness which cause low testos-
terone.24,177,187
In men undergoing hormonal therapy for prostate cancer, 
suppression of endogenous testosterone synthesis and 
blockade of the androgen receptor resulted in a beneficial 
effect on verbal memory but an adverse effect on spatial 
ability188 and visuomotor slowing and slowed reaction 
times in several attentional domains;189 plasma amyloid 
levels increased as T levels decreased.190 Discontinuation of 
treatment resulted in improved memory but not visuospatial 
abilities.190 One of the possible protective mechanisms of 
action of T would be through its conversion into estradiol 
(E2), the most potent estrogen. Both serum E2 and T levels 
were lower in men with AD compared to age-matched 
controls.191,192 E2 could exert protective effects on the brain 
structures in aging patients.193
Trials of testosterone therapy in men to evaluate its effects 
on measures of cognitive function and memory to date were 
all relatively small and of a relatively short duration and 
have shown mixed results.177,194 Small-scale T intervention 
trials in elderly men suggest that some cognitive deficits 
may be reversed, at least in part, by short term T supplementa-
tion.178Androgen supplementation in elderly hypogonadal 
men improves spatial cognition117,195 and verbal fluency196,197 
and in elderly men without dementia, it may reduce working 
memory errors.198 In addition, transdermal testosterone 
or DHT treatment in men aged 34 to 70 years improved 
verbal memory and spatial memory respectively,199 and 
intramuscular testosterone improved verbal and spatial 
memory and constructional abilities in non-hypogonadal 
men with mild cognitive impairment and Alzheimer’s 
disease.200 In one study of healthy men aged 50 to 90 years, 
intramuscular testosterone alone or in combination with 
anastrozole improved spatial memory, whereas verbal Therapeutics and Clinical Risk Management 2009:5 435
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memory only improved in testosterone-treated men in the 
absence of anastrozole, raising the possibility that part 
of the effect of exogenous testosterone is mediated by its 
aromatization to estradiol.200
However, in men with Alzheimer’s disease testosterone 
treatment appeared to improve quality of life without 
impacting on measures of cognition.201 In a randomized, 
placebo-controlled crossover trial intramuscular testosterone 
therapy resulted in decreased verbal memory.202 In other 
placebo-controlled randomized trials, one of which studied 
patients with Alzheimer’s dementia and low testosterone 
levels,203 reported imprecise effects on several dimensions of 
cognition, none of which was significant after pooling.203,204
Therefore, although the evidence from observational 
studies is not uniform, lower free testosterone appears to be 
associated with poorer outcomes on measures of cognitive 
function, particularly in older men and testosterone therapy 
in hypogonadal men may have some benefit for cognitive 
performance.
improving metabolic syndrome  
and diabetes type 2, cardiovascular disease
Many of the components of the metabolic syndrome (obesity, 
hypertension, dyslipidemia impaired glucose regulation, and 
insulin resistance) are also present in hypogonadal men. 
Lower testosterone levels are associated with surrogate 
markers for cardiovascular disease, including less favorable 
carotid intima medial thickness205–207 ankle/brachial index as 
a measure of peripheral arterial disease208 and calcific aortic 
atheroma.209 Endogenous testosterone concentrations are 
inversely related to mortality due to cardiovascular disease 
and all causes. Low testosterone may be a predictive marker 
for those at high risk of cardiovascular disease.8 Thus, lower 
testosterone levels, erectile dysfunction and conditions 
associated with higher cardiovascular risk appear to be 
interrelated.210,211 Obesity induces a decrease of T levels 
via a decrease in SHBG levels, and morbid obesity also 
induces a decrease of FT.212 There is evidence to suggest 
that an inverse relationship exists between serum testos-
terone levels and the degree of obesity in men.213,214 There 
is a close relationship between obesity and low serum tes-
tosterone levels in healthy men.215 Twenty percent to 64% 
of obese men have a low serum total or free testosterone 
level.216 Visceral obesity is more strongly inversely related 
to total and free testosterone levels than other forms of 
obesity.217,218 The Relationship between reduced testosterone 
and obesity in men can be explained by the hypogonadal-
cytokine-obesity cycle219,220 and it exhibits antiatherogenic 
effects at the tissue level, whether mediated by classical or 
nonclassical pathways.221,222
Initially cross-sectional studies but later also longitudinal 
studies were able to confirm that low testosterone levels 
and sex hormone-binding globulin (SHBG) were predictive 
of the metabolic syndrome, not only in obese men but also 
in men with a body mass index (BMI)  25 kg/m2.223,224 
The metabolic syndrome and type 2 diabetes mellitus are 
associated with low plasma testosterone34,225,226 and insulin 
sensitivity.34,227,228 There is positive correlation between 
serum testosterone levels and insulin sensitivity in men across 
the full spectrum of glucose tolerance229 and an improvement 
of insulin sensitivity was noted after replacement.230 Although 
Abate et al231 found no association between low plasma 
levels of bioavailable testosterone and insulin resistance in 
eugonadal men; a recent larger study (NHANES [National 
Health and Nutrition Examination Survey]) showed that 
low free and bioavailable testosterone levels, even in the 
normal range, are associated with diabetes, independent of 
adiposity.216 Serum testosterone should be measured in men 
with type 2 diabetes mellitus with symptoms suggestive of 
testosterone deficiency. The effects of testosterone admin-
istration on glycemic control of men with diabetes mellitus 
are much less certain.232–234 By increasing lean body mass and 
reducing fat mass, testosterone therapy modulates insulin 
resistance and risk of metabolic syndrome.232
Studies on androgen replacement in elderly men 
on LDL-C and HDL-C are controversial.235,236 The 
correlation between testosterone levels and HDL-C and insu-
lin sensitivity is only observed within the physiologic male 
concentration range of testosterone.237 A physiologic dose 
of androgens did not cause significant change in lipids.238 
A recent randomized controlled trial showed decrease 
in high-density lipoprotein cholesterol.239 A 24-week, 
multi-center, randomized, parallel-group study by Dobs 
et al240 of transdermal and intramuscular administration of 
androgens in 58 men did not detect any significant change 
in HDL levels or in the ratio of total cholesterol to HDL in 
either group, apart from the mode of therapy. In addition, 
testosterone replacement decreases lipoprotein (a).19 
The mechanism of the fall in lipids might be related to 
the decrease in the visceral abdominal fat mass241 under 
the influence of androgens, which inhibit lipoprotein lipase 
activity and increase lipolysis242,243 with improvement of 
insulin sensitivity and mobilization of triglycerides from 
abdominal fat tissue.244 Supraphysiological T levels induce 
an increase in LDL-C and a decrease of HDL-C245–247 and 
may increase the risk of cardiovascular disease.Therapeutics and Clinical Risk Management 2009:5 436
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Low androgen levels increase the risk of cardiovascular 
disease in men.236 Data are lacking as to whether higher 
testosterone levels predict reduced incidence of combined 
nonfatal and fatal major cardiovascular events.101 The inverse 
correlation between T levels and the severity of coronary artery 
disease248 may be related to the fact that low androgen levels 
are accompanied by an accumulation of abdominal visceral 
fat,249–251 which is known to be associated with increased 
cardiovascular risk factors252 impaired glucose tolerance, and 
non-insulin-dependent diabetes mellitus (syndrome X).253
No consistent relationship between the levels of free 
or total testosterone and coronary atherosclerosis in men 
undergoing coronary angiography has been observed.151,254 
Testosterone-replacement therapy does not increase the 
incidence of cardiovascular disease or events such as 
myocardial infarction, stroke, or angina.88 A meta-analysis255 
in 2007 concluded that the current available evidence shows 
no association between testosterone replacement therapy 
and cardiac events. Transdermal testosterone replacement 
therapy was found to be beneficial for men with chronic stable 
angina as they had greater angina-free exercise tolerance than 
placebo-treated controls.151
However, trials of testosterone therapy generally have 
not been designed or adequately powered to detect effects on 
clinically significant cardiovascular events.86,256 The outcome 
of most studies in men report either a favorable or neutral 
effect of normal T levels on cardiovascular disease in men. The 
administration of T in physiological concentration increases 
coronary blood flow in patients with coronary heart disease.257 
Beneficial effects on endothelial function258 and myocardial 
ischemia have also been demonstrated,248,259,260 but not with 
cardiovascular mortality.257,258 In addition, testosterone has a 
negative correlation with fibrinogen, plasminogen activator 
inhibitor-1261 and a direct effect on several vasoactive factors 
such as endothelin,262 prostacyclin, thromboxane A2 and 
platelet aggregation,263 blood coagulation, and fibrinolysis, 
respectively.248,261
Thus, although lower testosterone levels are associated 
with higher cardiovascular risk and to an extent with mortality 
in aging men, randomized controlled clinical trials of 
adequate size and duration are needed to determine whether 
testosterone therapy will reduce morbidity and mortality from 
cardiovascular disease in hypogonadal or eugonadal men.
improving anemia
Endogenous androgens are known to stimulate erythropoiesis; 
increase reticulocyte count, blood hemoglobin levels and 
bone marrow erythropoietic activity in mammals, whereas 
castration has opposite effects. Testosterone deficiency 
results in a 10% to 20% decrease in the blood hemoglobin 
concentration, which can result in anemia.264,265 Young 
hypogonadal men usually have fewer red blood cells and 
lower hemoglobin levels than age-matched controls, whilst 
healthy older men also may have lower hemoglobin than 
normal young men. The main androgen involvement in the 
mechanism of normal hematopoiesis is thought to involve 
direct stimulation of renal production of erythropoietin by 
testosterone. Moreover, the latter may also act directly on 
erythropoietic stem cells.265
Risks of testosterone replacement 
therapy
The risks of testosterone replacement therapy depend upon 
age, life circumstances, and other medical conditions.26 There 
is a risk for prostate cancer and worsening symptoms of 
benign prostatic hypertrophy, liver toxicity and tumor, wors-
ening symptoms of sleep apnea and congestive heart failure, 
gynecomastia, infertility and skin diseases. Testosterone replace-
ment therapy is not appropriate for men who are interested 
in fathering a child because exogenous testosterone will 
suppress the HPT axis. The risks of testosterone replacement 
therapy are summarized in Table 3.
The prostate and testosterone 
replacement therapy
In aging men with late-onset hypogonadism, TRT may 
normalize serum androgen levels but appears to have 
little effect on prostate tissue androgen levels and cellular 
functions266 and causes no significant adverse affects on the 
prostate.267 At the present time, there is no conclusive evidence 
that testosterone therapy increases the risk of prostate cancer 
or benign prostatic hyperplasia (BPH).45,268,269
Benign prostatic hyperplasia
It is well known that the presence of androgen is required for 
the development of benign prostatic hyperplasia. Testosterone 
Table 3 Potential risks for testosterone replacement therapy
Stimulate growth of prostate cancer and breast cancer
Worsen symptoms of benign prostatic hypertrophy  
Cause liver toxicity and liver tumor
Cause gynecomastia
Cause erythrocytosis
Cause testicular atrophy and infertility
Cause skin diseases
Cause or exacerbate sleep apneaTherapeutics and Clinical Risk Management 2009:5 437
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supplements increase prostate volume with, eventually 
mild increase in prostate specific antigen (PSA) levels in 
old men.90,117,270 Although a meta-analysis58 showed that the 
total number of prostate events combined was significantly 
greater in testosterone-treated men than in placebo-treated 
men, the majority of events are due to prostate biopsy; and the 
marked reduction in serum testosterone caused by chemical 
or surgical castration causes reduced prostate volume. At the 
same time, many studies271–273 have failed to show significant 
exacerbation of voiding symptoms attributable to benign 
prostatic hyperplasia during testosterone supplementation, 
and complications such as urinary retention have not occurred 
at higher rates than in controls receiving placebo nor has 
there been any difference in the urine flow rates, postvoiding 
residual urine volumes, and prostate voiding symptoms 
with patients receiving treatment in these studies. The poor 
correlation between prostate volume and urinary symptoms 
explain this illogicality.
Finally, although there are no compelling data to suggest 
that testosterone treatment exacerbates lower urinary tract 
symptoms (LUTS) or promotes acute urinary retention, severe 
LUTS, due to BPH, represent a relative contraindication 
which is no longer applicable after successful treatment of 
lower urinary tract obstruction.45
Prostate cancer
Prostate cancer is well known to be, in the majority of 
cases, an androgen sensitive disease, and prostate cancer 
has been treated in patterns designed to lower testosterone 
levels.270 Androgen replacement therapy is an absolute 
contraindication. There is also no good evidence that 
testosterone treatment will convert subclinical prostate cancer 
to clinically detectable prostate cancer,45 although some case 
reports reported this correlation.274,275 In a retrospective analy-
sis of hypogonadal men who underwent prostate biopsy prior 
to testosterone replacement therapy, no increase in the risk 
of prostate cancer in men was revealed compared to those 
without prostatic intraepithelial neoplasia at baseline.276
The prevalence of prostate cancer in many studies 
receiving testosterone replacement therapy was similar 
to that in the general population.67,277 So far, there is no 
compelling evidence that testosterone has a causative role 
in prostate cancer.271,272,278,279 In fact, it should be recognized 
that prostate cancer becomes more prevalent exactly at the 
time of a man’s life when testosterone levels decline. At a 
median of 19 months of TRT hypogonadal patients with a 
history of prostate cancer had no PSA recurrence and had 
statistically significant improvements in total testosterone 
and hypogonadal symptoms. In highly select patients after 
radical retropubic prostatectomy TRT can be administered 
carefully and with benefit to hypogonadal patients with 
prostate cancer.280 Hormonal replacement in patients that 
underwent castration seems to be feasible in improving 
intense symptoms associated with androgen deprivation. 
After 18 months, no evidence of recurrence was noted. 
It is an experimental alternative for highly symptomatic 
patients, but the short follow-up and the small number of 
patients cannot allow for definitive conclusions and should 
be studied further.281 A recent prospective study282 did not 
show definitive data to confirm the relationship between 
serum sex hormones and prostate cancer. There is, however, 
unequivocal evidence that testosterone can stimulate growth 
and aggravate symptoms in men with locally advanced and 
metastatic prostate cancer.283,284 Men successfully treated 
for prostate cancer and diagnosed with hypogonadism are 
candidates for testosterone replacement after a prudent inter-
val if there is no clinical or laboratory evidence of residual 
cancer.285,286 In addition, no effect was found of testosterone 
replacement therapy on PSA levels287–289 and the change 
in PSA were not influenced by the mode of testosterone 
replacement therapy, patient age, or baseline levels of PSA 
or testosterone.290
The online prostate cancer risk calculator is one of the 
most commonly used tools to assist the clinician in assessing 
the risk of prostate cancer.291–293 All men who present for TRT 
should undergo prostate biopsy if they have abnormal PSA 
level or abnormal result on digital rectal examination with 
low threshold to do or repeat prostate biopsy if the PSA level 
or digital rectal exam changes. Prostatic biopsy or referral to 
a urologist is recommended if PSA rises above 4.0 ng/mL 
or if it increases either by more than 1.5 ng/mL/year or by 
more than 0.75 ng/mL/year over 2 years,294 or if PSA rises 
by more than 1.0 ng/mL in the first 6 months of treatment or 
by more than 0.4 ng/mL/year thereafter.295
In summary, there is no convincing evidence that the 
normalization of testosterone serum levels in men with low 
levels is deleterious. TRT can be cautiously considered in 
selected hypogonadal men treated with curative intent for 
prostate and without evidence of active disease.296
Liver problems
Benign and malignant hepatic tumors, intrahepatic 
cholestasis, hepatotoxicity, and liver failure have been 
reported with testosterone replacement therapy.297,298 These 
unfavorable hepatic effects do not appear to be associated 
with transdermal or intramuscular injections. For this Therapeutics and Clinical Risk Management 2009:5 438
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reason the oral forms of testosterone, with the exception 
of testosterone undecanoate, are discouraged. Other liver 
abnormalities associated with TRT include Peliosis hepatis, 
hepatocellular adenoma, and carcinoma.299
The risk of polycythemia
There is a correlation between high testosterone levels 
and high hemoglobin, most likely because testosterone 
stimulates erythropoiesis. Erythrocytosis can develop during 
testosterone treatment, especially in older men treated by 
injectable testosterone preparations.45 Hemoglobin at puberty 
increases 15% to 20% in boys, men have higher levels of 
hemoglobin than women, and hypogonadism causes a decline 
in hemoglobin levels that can be restored with testosterone 
replacement therapy.139,300 But the elevation in hemoglobin 
above certain levels may have bad outcomes, particularly 
in elderly, because the increase in blood viscosity could 
exacerbate vascular disease in the coronary, cerebrovascular, 
or peripheral vascular circulation, especially in people with 
other diseases that cause secondary polycythemia, ie, chronic 
obstructive pulmonary disease.301–303 Injection is associated 
with higher potentials for erythrocytosis than topical prepa-
rations.240 Snyder et al noticed that erythrocytosis occurred 
in 5.5% of scrotal transdermal users, and the majority of 
changes took place over the first three months of treatment.92 
It has been demonstrated that testosterone dosage correlates 
with the incidence of erythrocytosis,67 The frequency of 
polycythemia (hematocrit over 51%) is related most of the 
time to supra-physiological levels.240 The resolution of 
erythrocytosis (hematocrit  52%), untreated obstructive 
sleep apnea, or untreated severe congestive heart failure, is 
required before starting on testosterone treatment.19,58,304
Periodic hematological assessment is indicated (ie, before 
treatment, then at 3 to 4 months and at 12 mo in the first year 
of treatment and annually thereafter). While it is not yet clear 
what critical threshold is a desirable, dose adjustment and/or 
periodic phlebotomy may be necessary to keep hematocrit 
below 52% to 55%.45,58,305
Other effects of testosterone 
replacement therapy
Psychotic symptoms, excessive libido and aggression, 
in addition to physical and psychological dependence 
and withdrawal syndromes have been rarely described 
with testosterone treatment,306,307 though the validity of 
testosterone or the cause is uncertain. Kenny et al204 did not 
find that significant changes in behavior, function, depression, 
or cognitive performance occurred following 12 weeks of 
testosterone replacement in men with low testosterone levels 
and early-to-moderate cognitive impairment.
Gynecomastia is a benign complication of testosterone 
treatment. It is related to aromatization of testosterone into 
estradiol in peripheral fat and muscle tissue. Even the ratio 
of estradiol to testosterone usually remains normal. It occurs 
especially with testosterone enanthate or cypionate. Dose 
adjustment may be necessary.
Diminished testicular size and compromised fertility 
during testosterone replacement therapy occur because of 
the down-regulation of gonadotropins.308 The administration 
of exogenous testosterone as a means of male contraception 
is under study.309 In these men, azoospermia usually results 
within approximately 10 weeks of beginning therapy. 
Rebound of the sperm count to baseline levels occurs 
within six to 18 months of cessation, and subsequent 
fertility has been demonstrated.310 Supraphysiologic doses 
of androgens may cause decreased testicular size, and 
azoospermia.311
Testosterone-replacement therapy has been associated 
with exacerbation of sleep apnea.312,313 The effect of 
testosterone is not on the dimensions of the upper airway, 
but it most likely contributes to sleep disorder breathing 
by central mechanisms.314 The development of signs and 
symptoms of obstructive sleep apnea during testosterone 
therapy warrants a formal sleep study and treatment with 
continuous positive airway pressure (CPAP) if necessary. 
If the patient is unresponsive or cannot tolerate CPAP, the 
testosterone must be reduced or discontinued.
Transdermal testosterone-replacement therapy is 
associated with a variety of skin reactions, mainly erythema 
or pruritus, which are more common with patches than with 
gel preparations.67 Intramuscular injections of testosterone 
can cause local pain, soreness, bruising, erythema, swelling, 
nodules, or furuncles.315 Supraphysiologic doses of androgens 
may cause acne.311
Testosterone is anabolic, and it will cause some nitrogen, 
sodium and water retention. Edema may be worsened in 
patients with preexisting cardiac, renal, or hepatic disease. 
Hypertension has rarely been reported.316
Hyperandrogenism was reported in a female whose 
partner was using testosterone gel.317
Monitoring patients  
on testosterone replacement
Laboratory parameters that should be monitored before and 
during treatment include PSA, hemoglobin, hematocrit, 
lipid profiles, and liver function tests. Patients should also Therapeutics and Clinical Risk Management 2009:5 439
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be monitored for signs of edema, gynecomastia, sleep apnea, 
lower urinary tract symptoms, and low BMD. There are 
clinical practice guidelines from the Endocrine Society for 
monitoring patients receiving TRT.45 Testosterone level, 
digital rectal exam, PSA, hematocrit, BMD, lipids, and liver 
function tests should be checked at baseline then evaluate 
the patient 3 and 6 months after treatment starts and then 
annually to assess whether symptoms have responded to 
treatment and whether the patient is suffering from any 
adverse effects.
Testosterone levels should be monitored 3 months after 
initiation of testosterone therapy. A mid-morning total 
serum testosterone level should be obtained. A target range 
of 400 to 500 ng/dL (14.0 to 17.5 nmol/L) for older men is 
suggested. However, if there is no symptomatic response, 
higher levels may be necessary. For injectable testosterone, 
the serum level can be measured between injections. For men 
treated with a transdermal testosterone patch, the serum level 
should be measured 3 to 12 hours after patch application. 
In patients receiving buccal testosterone tablets, the serum 
level should be measured immediately before application 
of a fresh system. Patients on testosterone gel may have 
levels checked anytime after at least 1 week of therapy.45 
In all cases, bioavailable testosterone levels should also be 
monitored as testosterone therapy lowers SHBG.
The hematocrit should be checked at baseline, at 3 and 
6 months, and then annually. If hematocrit is more than 
54%, stop therapy until hematocrit decreases to a safe 
level; evaluate the patient for hypoxia and sleep apnea; 
reinitiate therapy with a reduced dose. BMD of lumbar 
spine and/or femoral neck should be measured at baseline 
every 1 to 2 years of testosterone therapy in hypogonadal 
men with osteoporosis or low trauma fracture. A digital 
rectal examination and PSA level should be obtained before 
initiating treatment, at 3 months, and then in accordance 
with guidelines for prostate cancer screening, depending on 
the age and race of the patient. A urologic consultation is 
mandatory if any of the following is present (Table 4).
The use of testosterone preparations should be discussed 
with patients and then closely monitored for efficacy and 
toxicities.3,318–320 Failure to benefit from clinical manifes-
tations should result in discontinuation of treatment after 
3 months for libido and sexual function, muscle function, and 
improved body fat; and a longer interval for bone mineral 
density. Further investigation for other causes of symptoms 
is then mandatory.45
Contraindications to testosterone 
replacement therapy
Before starting patients on TRT, health care providers 
must rule out contraindications to treatment (Table 5). The 
presence of a clinical prostatic carcinoma is an absolute 
contraindication for HRT and should be carefully excluded 
by PSA, rectal examination and, eventually, biopsy before 
starting any therapy.45 There is also no clear recommendation 
for men successfully treated for prostate cancer who would 
be potential candidates for testosterone substitution after a 
‘prudent’ interval if there is no clinical or laboratory evidence 
of residual cancer.45
The presence of breast cancer is also a contraindication 
for TRT as well as a prolactinoma, as their growth may 
be stimulated by HRT.26 Very high risk of serious adverse 
outcomes,undiagnosed prostate nodules or indurations, unex-
plained PSA elevation, erythrocytosis (hematocrit  50%), 
severe lower urinary tract symptoms with benign prostatic 
hyperplasia with an International Prostate Symptom Score 
(IPSS)  19, and unstable congestive heart failure (class III 
or IV), untreated obstructive sleep apnea are considered 
as moderate- to high-risk factors for potential adverse 
outcomes.26,45,319
Conclusion
Male hypogonadism and its treatment is a rapidly evolving 
area. While male hypogonadism has previously been 
underdiagnosed, the apparently increasing incidence and 
expanding range of treatment options may facilitate greater 
Table 4 when a urological consultation is needed
1. Verified serum PSA concentration more than 4.0 ng/mL
2. An increase in serum PSA concentration more than 1.4 ng/mL within any 12-month period of testosterone treatment
3.   A PSA velocity of more than 0.4 ng/mL/year using the PSA level after 6 months of testosterone administration as the reference (only applicable if PSA data 
available 2 years)
4.  Detection of a prostatic abnormality on digital rectal examination
5. An American Urological Association (AUA) or International Prostate Symptom Score (IPSS) prostate symptom score of more than 19
Abbreviation: PSA, prostate specific antigen.Therapeutics and Clinical Risk Management 2009:5 440
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awareness of the condition. The symptoms in the elderly have 
a complex origin. It may be reasonably assumed that the age-
associated decrease in T levels is in part responsible for the 
symptoms of aging. The benefits and risks of testosterone 
therapy must be clearly discussed with the patient and 
assessment of prostate and other risk factors considered 
before commencing testosterone treatment. There is some 
benefit from testosterone replacement therapy on muscle 
mass and strength, fat mass, BMD, sexual function, mood 
and general sense of well-being. Therefore, it seems logical 
to consider that in elderly men with subnormal T levels 
and clinical symptoms suggestive of androgen deficiency, 
hormone replacement therapy in combination with physical 
activity (resistance training) and adequate nutrition will 
result in an optimal increase in muscle strength, BMD, 
and general sense of well-being. However, data on clinical 
effects of androgen substitution, such as cardiovascular 
morbidity and mortality, falls and bone fracture rates are not 
yet available. Response to testosterone treatment should be 
assessed. If there is no improvement of symptoms and signs, 
treatment should be discontinued and the patient investigated 
for other possible causes of the clinical presentations. The 
major contraindication for androgen supplementation is the 
presence of a prostatic carcinoma.
Future of TRT
Hypogonadism may present to a range of specialties. 
Previously, late-onset hypogonadism has not been well 
understood. Studies conducted to date have been too small 
to address potential long-term adverse effects, and there are 
risks in extrapolating benefit from epidemiological studies. 
Many questions in the treatment of hypogonadism remain 
unanswered, and there is a need for large clinical trials; or 
at least a meta-analysis of the extensive short-term data 
combined with analysis of long-term clinical experience 
which many physicians working in the field now have; to 
assess the long-term benefits and risks of TRT in older men 
with late-onset hypogonadism.
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